Advertisement
Research Article

Predictive Markers of Efficacy for an Angiopoietin-2 Targeting Therapeutic in Xenograft Models

  • Gallen Triana-Baltzer,

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Adam Pavlicek,

    Affiliation: Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    Current address: Regulus Therapeutics, San Diego, California, United States of America

    X
  • Ariadne Goulart,

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    Current address: Isis Therapeutics, Carlsbad, California, United States of America

    X
  • Hanhua Huang,

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Steven Pirie-Shepherd mail,

    Steven.Pirie-Shepherd@pfizer.com

    Affiliation: Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Nancy Levin

    Affiliation: CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America

    X
  • Published: November 14, 2013
  • DOI: 10.1371/journal.pone.0080132

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.